ATyr Pharma Faces Investor Suit Over Failed Drug Trial
Rare disease biotech aTyr Pharma Inc. and its CEO have been hit with a proposed shareholder class action accusing them of misleading the public about the efficacy of aTyr's lung disease...To view the full article, register now.
Already a subscriber? Click here to view full article